Filter
80
Filtered Results: 80
Text search:
DNDi
Featured
Recommendations
9
New Publications
10
Language
Document type
Studies & Reports
25
No document type
18
Guidelines
7
Strategic & Response Plan
7
Manuals
5
Resource Platforms
5
Videos
4
Fact sheets
4
Situation Updates
3
Infographics
2
Countries / Regions
Global
10
Latin America and the Carribbean
6
Africa
4
Colombia
3
Ethiopia
3
Kenya
2
West and Central Africa
2
East and Southern Africa
2
Southern Africa
2
Brazil
2
Asia
1
Congo, Democratic Republic of
1
South–East Asia Region
1
Uruguay
1
Argentina
1
Bangladesh
1
Uganda
1
Zambia
1
India
1
Authors & Publishers
Publication Years
Category
Countries
17
Clinical Guidelines
12
Pharmacy & Technologies
3
Public Health
1
Toolboxes
NTDs
46
HIV
6
Global Health Education
3
COVID-19
2
Pharmacy
2
AMR
2
TB
1
Planetary Health
1
Health Financing Toolbox
1
NCDs
1
1 billion people are at risk of infection with leishmaniasis, a neglected disease strongly linked to poverty. There’s no single, simple cure: current treatments are complex and need to be adapted to the form of the disease and geographical region.
Leishmaniasis is among the most neglected diseases. The most common form is cutaneous leishmaniasis that forms lesions on the skin.
The only treatment available for cutaneous leishmaniasis is highly toxic. In some cases, patients have died because of the treatment, even though cutaneous leishmania...
Website last accessed on 14.04.2023
Health workers Luke (Kenya), Juliana (Colombia), and Shishu (India) share the same hope for their patients with leishmaniasis: simple, oral treatments. For the first time ever, it seems leishmaniasis research is moving from neglect to a sense of hope.
The Leishmaniasis East Africa Platform (LEAP) was established to support the generation of scientific evidence for the development and distribution of new treatments for leishmaniasis in Eastern Africa.
Diabetes Poster - Does your child show any of these symptoms?
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge...
Cutaneous Leishmaniasis (CL) is a painful disease that exerts a serious toll on societies around the world that are afflicted by it. Although not life-threatening, the skin ulcers and scars it causes can lead to isolation and psychosocial pathologies due to social stigma, and its occurrence is often...
Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.
PLoS Neglected Tropical diseases August 16, 2021 https://doi.org/10.1371/journal.pntd.0009697
Chagas disease, also known as American trypanosomiasis, is a neglected tropical disease transmitted by triatomine insects, first identified in 1909. Chagas disease affects approximately 6–7 million peop...
PLoS Negl Trop Dis 15(8): e0009697. Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects ~6–7 million people worldwide. Significant limitations still exist in our understanding of CD. Harnessing individual participant data (IPD) from studies could support more in-depth analyses t...
2nd edition
Lessons from the STEP-TB Project.
Accessed November 2017.
Meeting Report
27–30 June 2017 Manila, Philippines
WHO and UNITAID
in collaboration with IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials) network, PENTA (Paediatric European Network for Treatment of AIDS) foundation and experts from the Paediatric Antiretroviral Working Group
Technology landscape
